BioSpace News Archive

Biodesix, Inc. announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society 2022 International Conference.

Vizient, Inc. today announced it has expanded Novaplus® Enhanced Supply to include three new medical/surgical categories and an antidotes category for pharmaceutical supplies.

Hyundai Bioscience announced on the 11th that phase 2 clinical trial of CP-COV03 for COVID-19 patients has begun.

Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ended March 31, 2022, along with a corporate update.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported pipeline and business progress and first quarter 2022 financial results.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter ended March 31, 2022.

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the Company will host a symposium with Key Opinion Leaders on Dravet Syndrome and recent therapeutic developments within the competitive landscape.

Lannett Company, Inc. announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials.

Hygieia, a digital therapeutics company, announced the official launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes.

MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), today announced that the first patient has been randomized and dosed, in a U.S. site, in its global Phase 2 clinical trial evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS).